CPA1 and Cirrhosis: This could be a benefit of the mechanism of action of this therapy compared with NSBBs, with which hypotension often occurs in patients with CP-B cirrhosis.25 However, drug-related orthostatic dysregulation occurred in 5 patients receiving BI 685509 (n = 1, CP-A 3 mg BID; n = 2 each per CP-B 2 mg BID and 3 mg BID).